ES2392551T3 - Composiciones que comprenden quitosano adecuadas para el tratamiento terapéutico global o la prevención global de síndrome metabólico - Google Patents
Composiciones que comprenden quitosano adecuadas para el tratamiento terapéutico global o la prevención global de síndrome metabólico Download PDFInfo
- Publication number
- ES2392551T3 ES2392551T3 ES07726617T ES07726617T ES2392551T3 ES 2392551 T3 ES2392551 T3 ES 2392551T3 ES 07726617 T ES07726617 T ES 07726617T ES 07726617 T ES07726617 T ES 07726617T ES 2392551 T3 ES2392551 T3 ES 2392551T3
- Authority
- ES
- Spain
- Prior art keywords
- chitosan
- composition according
- global
- metabolic syndrome
- ascorbic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 43
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 42
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 230000002265 prevention Effects 0.000 title claims abstract description 15
- 230000001225 therapeutic effect Effects 0.000 title description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 36
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 18
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 18
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 18
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 10
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 9
- 239000011975 tartaric acid Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 230000004872 arterial blood pressure Effects 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 230000007170 pathology Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 206010033307 Overweight Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 1
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 241001580017 Jana Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000002956 ash Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20060384 | 2006-03-03 | ||
| IT000384A ITMI20060384A1 (it) | 2006-03-03 | 2006-03-03 | Composizioni comprendenti chitosano atte al trattamento terapeutico complessivo o alla prevenzione complessiva della sindrome metabolica |
| PCT/EP2007/052023 WO2007099170A1 (en) | 2006-03-03 | 2007-03-02 | Compositions comprising chitosan suitable for comprehensive therapeutic treatment or comprehensive prevention of the metabolic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2392551T3 true ES2392551T3 (es) | 2012-12-11 |
Family
ID=38019452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07726617T Active ES2392551T3 (es) | 2006-03-03 | 2007-03-02 | Composiciones que comprenden quitosano adecuadas para el tratamiento terapéutico global o la prevención global de síndrome metabólico |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9050356B2 (enExample) |
| EP (1) | EP1996207B1 (enExample) |
| JP (1) | JP5557451B2 (enExample) |
| ES (1) | ES2392551T3 (enExample) |
| IT (1) | ITMI20060384A1 (enExample) |
| MX (1) | MX2008011289A (enExample) |
| PL (1) | PL1996207T3 (enExample) |
| WO (1) | WO2007099170A1 (enExample) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54148090A (en) * | 1978-05-11 | 1979-11-19 | Ajinomoto Co Inc | Peroral cholesterol-depressant |
| US4223023A (en) | 1978-10-12 | 1980-09-16 | Ivan Furda | Nonabsorbable lipid binder |
| JP2614297B2 (ja) * | 1988-12-27 | 1997-05-28 | 三栄源エフ・エフ・アイ株式会社 | ソーマチンの凝集・分離防止及び甘味改善法 |
| JPH04108734A (ja) * | 1990-08-29 | 1992-04-09 | Kurita Water Ind Ltd | 降コレステロール剤 |
| JP2667351B2 (ja) * | 1992-03-24 | 1997-10-27 | 麒麟麦酒株式会社 | 食餌脂質消化吸収阻害剤および飲食品 |
| JP2507907B2 (ja) * | 1992-06-08 | 1996-06-19 | 水産庁長官 | 血圧降下用の食品添加物質および抗高血圧剤 |
| US5550019A (en) * | 1993-05-26 | 1996-08-27 | La Jolla Cancer Research Foundation | Methods of identifying compounds which alter apoptosis |
| US6180148B1 (en) | 1996-05-28 | 2001-01-30 | Asama Chemical Co., Ltd. | Method for cooking fresh noodles in a microwave oven |
| US20030069206A1 (en) | 1998-07-10 | 2003-04-10 | Nichols Everett J. | Methods and kits for absorbing fat |
| PT1105123E (pt) | 1998-08-14 | 2004-08-31 | Hoffmann La Roche | Composicoes farmaceuticas contendo inibidores da lipase e quitosano |
| JP3371843B2 (ja) | 1999-02-25 | 2003-01-27 | 扶桑化学工業株式会社 | ロングライフ麺およびその製造方法 |
| US20020016307A1 (en) * | 1999-10-27 | 2002-02-07 | Mullins John Jason Gentry | Pharmaceutical composition with both a lipase inhibitor and a lipophilic polysaccharide and an improved method for treating adiposity |
| DE10054450A1 (de) | 2000-09-06 | 2002-03-28 | Guillermo Pasch Alonso | Verfahren zur Modifikation von Getreidemahlerzeugnissen, nach dem Verfahren hergestellte Produkte und deren Verwendung |
| JP5024807B2 (ja) * | 2001-03-21 | 2012-09-12 | 独立行政法人水産総合研究センター | 血圧上昇の抑制組成物 |
| JP2003113089A (ja) * | 2001-10-04 | 2003-04-18 | Gotoo Corporation:Kk | 脂質蓄積性阻害およびコレステロール低下作用を有するキトサン含有製剤および飲食品 |
| JP2003238602A (ja) * | 2002-02-20 | 2003-08-27 | Marino Forum 21 | 血糖値上昇抑制性物質 |
| ITRM20030127A1 (it) | 2003-03-24 | 2004-09-25 | Osvaldo Legnini | Composizione alimentare, pasta alimentare funzionale |
| KR100520007B1 (ko) * | 2003-05-19 | 2005-10-11 | 건 식 조 | 혈압 강하 기능을 가지는 키토산 함유 소금의 제조방법 |
| WO2005089731A2 (en) * | 2004-03-17 | 2005-09-29 | Novartis Ag | Use of renin inhibitors in therapy |
| CN1692782A (zh) | 2005-06-26 | 2005-11-09 | 苟春虎 | 降压好酸奶片 |
| RU2290185C1 (ru) | 2005-07-26 | 2006-12-27 | Дмитрий Николаевич Мясников | Композиция для нормализации липидного обмена и снижения массы тела и способ её получения |
-
2006
- 2006-03-03 IT IT000384A patent/ITMI20060384A1/it unknown
-
2007
- 2007-03-02 PL PL07726617T patent/PL1996207T3/pl unknown
- 2007-03-02 WO PCT/EP2007/052023 patent/WO2007099170A1/en not_active Ceased
- 2007-03-02 MX MX2008011289A patent/MX2008011289A/es active IP Right Grant
- 2007-03-02 US US12/281,615 patent/US9050356B2/en active Active
- 2007-03-02 JP JP2008557733A patent/JP5557451B2/ja active Active
- 2007-03-02 ES ES07726617T patent/ES2392551T3/es active Active
- 2007-03-02 EP EP07726617A patent/EP1996207B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008011289A (es) | 2009-01-27 |
| ITMI20060384A1 (it) | 2007-09-04 |
| PL1996207T3 (pl) | 2013-01-31 |
| WO2007099170A1 (en) | 2007-09-07 |
| JP2009531306A (ja) | 2009-09-03 |
| JP5557451B2 (ja) | 2014-07-23 |
| EP1996207B1 (en) | 2012-08-08 |
| US9050356B2 (en) | 2015-06-09 |
| US20090258839A1 (en) | 2009-10-15 |
| EP1996207A1 (en) | 2008-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marcus et al. | Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. | |
| Wright et al. | Treatment of oral thrush in HIV/AIDS patients with lemon juice and lemon grass (Cymbopogon citratus) and gentian violet | |
| KR101242596B1 (ko) | 동충하초 추출물 또는 이로부터 분리된 코디세핀을 유효성분으로 하는 불면증 개선 및 치료용 약학 조성물 | |
| US20230127906A1 (en) | Formulations for extending lifespan and healthspan | |
| CN101239069A (zh) | 可提供活性甲基或参与甲基转移的化合物的应用 | |
| JP2018502079A (ja) | ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び／又は刺激におけるその使用 | |
| McIntyre et al. | Prevalence of hypertension, obesity and smoking in three Indian communities in northwestern Ontario | |
| Rangineni et al. | Diuretic, hypotensive, and hypocholesterolemic effects of Eclipta alba in mild hypertensive subjects: a pilot study | |
| US7645795B2 (en) | Method for treating amyotrophic lateral sclerosis | |
| ES2392551T3 (es) | Composiciones que comprenden quitosano adecuadas para el tratamiento terapéutico global o la prevención global de síndrome metabólico | |
| Verma et al. | Vitamin B12 deficiency among vegetarian and non-vegetarian diabetic population receiving prolonged metformin based oral hypoglycemic agents therapy | |
| US20200100535A1 (en) | Dietary supplement for lowering blood sugar, increasing immunity, and increasing cardiac function and increasing physical stamina | |
| CN114177163B (zh) | 一种治疗高血压的药物 | |
| Chen et al. | Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo-and active-controlled, crossover thorough QT/QTc study in healthy adults | |
| Xiao et al. | The efficacy of cerebrolysin in patients with vascular dementia: Results of a Chinese multicentre, randomised, double-blind, placebo-controlled trial | |
| JP4779316B2 (ja) | ジコッピ配合モノアミン再取り込み阻害剤 | |
| WO2020233459A1 (zh) | 一种改善记忆的组合物及其制备方法 | |
| CN105919096B (zh) | 一种保健食品组合物及其制剂和用途 | |
| JP6565085B2 (ja) | 低血糖症状緩和剤 | |
| CN101803732A (zh) | 一种具有辅助降血脂功能的保健食品及其制备方法 | |
| Tran et al. | Shamanic Kambô Frog Hyponatremic Toxicity Leading to Brain Death: A Case Report | |
| Subramanian et al. | Cysticercosis of the oral cavity: an often misdiagnosed entity | |
| Panigrahi et al. | Routine Body Checkup & Good Health Tips for Elder Person | |
| Siriwardena | Specific health issues in ethnic minority groups | |
| CN105770087A (zh) | 一种治疗糖尿病、高脂血症、原发性高血粘度的蒙药组合物 |